Technical Analysis for RDHL - Redhill Biopharma Ltd.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 6.40 | -6.57% | -0.45 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Very Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | 0.00% | |
| New 52 Week Low | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| New 52 Week Closing Low | Bearish | -6.57% | |
| Narrow Range Bar | Range Contraction | -6.57% | |
| Oversold Stochastic | Weakness | -6.57% |
| Alert | Time |
|---|---|
| Fell Below Previous Day's Low | about 22 hours ago |
| Down 1% | about 22 hours ago |
| Possible NR7 | 1 day ago |
| Up 3% | 2 days ago |
| Bearish 180 Entry | 2 days ago |
Get a Trading Sidekick!
- Earnings date: 09/16/2024
Redhill Biopharma Ltd. Description
RedHill Biopharma Ltd., a biopharmaceutical company, engages in the acquisition and development of patent-protected new formulations and combinations of existing drugs in advanced stages of development. The company's pipeline includes six clinical stage therapeutic candidates comprising RHB-101, a once daily controlled release patented formulation of Carvedilol for the treatment of hypertension, heart failure, and left ventricular dysfunction; RHB-102, a once daily controlled release oral formulation of Ondansetron for the prevention of nausea and vomiting for oncology-support treatments; and RHB-103, a proprietary oral fast dissolving thin film formulation of rizatriptan for the treatment of acute migraine headaches. Its pipeline also consists of RHB-104, a patented antibiotics drug for the treatment of inflammatory bowel disease focused on Crohn's disease patients; RHB-105, an antibiotics and proton pump inhibitor proprietary drug targeting helicobacter pylori infection; and RHB-106, a patented formulation in tablet form for the preparation and cleansing of the gastrointestinal tract. RedHill Biopharma Ltd. was founded in 2009 and is based in Tel Aviv, Israel.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Autoimmune Disease Gastrointestinal Hypertension Antibiotics Heart Failure Dysfunction Inflammatory Bowel Disease Gastroenterology Thin Film Abdominal Pain Crohn's Disease Headache Migraine Nausea Proton Bacteria Gastrointestinal Tract Migraine Headache Treatment Of Hypertension Helicobacter Migraine Headaches Treatment Of Inflammatory Bowel Disease
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 2050.0 |
| 52 Week Low | 6.345 |
| Average Volume | 18,934 |
| 200-Day Moving Average | 197.53 |
| 50-Day Moving Average | 8.45 |
| 20-Day Moving Average | 7.73 |
| 10-Day Moving Average | 7.28 |
| Average True Range | 1.01 |
| RSI (14) | 16.67 |
| ADX | 63.63 |
| +DI | 9.59 |
| -DI | 46.36 |
| Chandelier Exit (Long, 3 ATRs) | 5.86 |
| Chandelier Exit (Short, 3 ATRs) | 9.38 |
| Upper Bollinger Bands | 8.94 |
| Lower Bollinger Band | 6.53 |
| Percent B (%b) | -0.05 |
| BandWidth | 31.08 |
| MACD Line | -2.23 |
| MACD Signal Line | -2.93 |
| MACD Histogram | 0.7015 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 7.20 | ||||
| Resistance 3 (R3) | 7.27 | 7.08 | 7.07 | ||
| Resistance 2 (R2) | 7.08 | 6.87 | 7.04 | 7.02 | |
| Resistance 1 (R1) | 6.74 | 6.75 | 6.64 | 6.67 | 6.98 |
| Pivot Point | 6.54 | 6.54 | 6.49 | 6.51 | 6.54 |
| Support 1 (S1) | 6.20 | 6.34 | 6.11 | 6.13 | 5.82 |
| Support 2 (S2) | 6.01 | 6.21 | 5.97 | 5.78 | |
| Support 3 (S3) | 5.67 | 6.01 | 5.73 | ||
| Support 4 (S4) | 5.60 |
